Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure

被引:20
|
作者
Cournot, Maxime [1 ,2 ]
Mourre, Fabien [1 ]
Castel, Fabienirie [3 ]
Ferrieres, Jean [2 ]
Destrac, Sylvain [1 ]
机构
[1] Ctr Hosp Val Ariege, Dept Cardiol, Foix, France
[2] INSERM, U558, Cardiovasc Epidemiol Unit, F-31073 Toulouse, France
[3] Ctr Hosp Val Ariege, Dept Gerontol, Foix, France
关键词
D O I
10.1016/j.ahj.2008.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In elderly patients hospitalized for decompensated heart failure, B-type natriuretic peptide (BNP) levels at discharge and the change in BNP during hospitalization may provide different information and may need to be taken into account simultaneously to best reflect the response to therapy. The aim of this study was to determine whether the most accurate risk stratification is obtained using BNP level after stabilization on treatment, the change in BNP under optimal treatment, or a combination of both markers. Methods This prospective cohort study included 157 consecutive patients aged >= 70 (mean, 83 years), hospitalized for decompensated heart failure. Clinical, radiologic, biologic, and ultrasonography data were collected on admission and at discharge. Results The median BNP level on admission was 1,057 pg/mL, and the mean change during hospitalization was -42%. Cardiac death or readmission were independently predicted by both predischarge BNP (best threshold: >360 pq/mL, HR 3.35 [1.94-5.75]) and the change in BNP levels (best threshold: -50%, HR 2.52 [1.59-4.01]). The highest event rate was observed in patients with both a predischarge BNP >= 360 pg/mL and a decrease <50% during hospitalization (HR 5.97 [2.98-11.94] compared with patients with a predischarge BNP <360 pg/mL and a decrease >= 50%, after adjustment for potential confounders). The remaining patients constituted an intermediate risk group (HR 3.13 [1.44-6.77]). Conclusion Predischarge BNP and inhospital BNP change should not be interpreted independently from each other. The highest risk group includes patients with a high predischarge BNP level corresponding to more than the half of the BNP on admission. These patients would benefit from close monitoring for signs of decompensation.
引用
收藏
页码:986 / 991
页数:6
相关论文
共 50 条
  • [41] The role of B-type natriuretic peptide in diagnosing acute decompensated heart failure in chronic kidney disease patients
    Kadri, Amer N.
    Kaw, Roop
    Al-Khadra, Yasser
    Abuamsha, Hasan
    Ravakhah, Keyvan
    Hernandez, Adrian V.
    Tang, Wai Hong Wilson
    ARCHIVES OF MEDICAL SCIENCE, 2018, 14 (05) : 1003 - 1009
  • [42] The Role of B-type Natriuretic Peptide in Diagnosing Acute Decompensated Heart Failure in Chronic Kidney Disease Patients
    Kadri, Amer
    Kaw, Roop
    Al-Khadra, Yasser
    Abuamsha, Hasan
    Ravakhah, Keyvan
    Hernandez-Diaz, Adrian
    Tang, W. H. Wilson
    CIRCULATION, 2017, 136
  • [43] Levels of B-type natriuretic peptide in chronic heart failure patients with and without diabetes mellitus
    Peng, Qiang
    Hu, Weitong
    Su, Hai
    Yang, Qing
    Cheng, Xiaoshu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (01) : 229 - 232
  • [44] B-type natriuretic peptide levels not increased in heart failure patients receiving thiazolidinediones.
    Granberry, N
    Tijerina, SL
    Balli, J
    Evans, MD
    PHARMACOTHERAPY, 2005, 25 (03): : 465 - 465
  • [45] Urinary B-type natriuretic peptide levels in the diagnosis and prognosis of heart failure
    Cortes, Raquel
    Rivera, Miguel
    Salvador, Antonio
    Garcia De Burgos, Fernando
    Bertomeu, Vicente
    Rosello-Lleti, Esther
    Martinez-Dolz, Luis
    Paya, Rafael
    Almenar, Luis
    Portoles, Manuel
    JOURNAL OF CARDIAC FAILURE, 2007, 13 (07) : 549 - 555
  • [46] B-type natriuretic peptide levels, obesity, and survival in advanced heart failure
    Horwich, TB
    MacLellan, WR
    Fonarow, GC
    CIRCULATION, 2004, 110 (17) : 554 - 554
  • [47] Not all patients with symptomatic heart failure have elevated B-type natriuretic peptide levels
    Hogenhuls, J
    Jaarsma, T
    Voors, AA
    Hillege, JL
    van Veldhuisen, DJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 164A - 164A
  • [48] Effects of nesiritide (B-type natriuretic peptide) in decompensated heart failure patients receiving beta-blockers
    Abraham, WT
    CIRCULATION, 2001, 104 (17) : 420 - 420
  • [49] Relationship between B-type natriuretic peptide plasma levels and echocardiography parameters in decompensated chronic heart failure patients treated with levosimendan
    MB Ferri
    RH Passos
    M Knobel
    M Nigri
    EJA Figueiredo
    RD Morsch
    P Silveira
    JMA Souza
    A Perez
    Critical Care, 10 (Suppl 1):
  • [50] Endogenous B-type natriuretic peptide: A limb of the regulatory response to acutely decompensated heart failure
    Hobbs, Robert E.
    Mills, Roger M.
    CLINICAL CARDIOLOGY, 2008, 31 (09) : 407 - 412